Navigation Links
HIV/AIDS vaccine shows long-term protection against multiple exposures in non-human primates
Date:3/7/2012

An Atlanta research collaboration may be one step closer to finding a vaccine that will provide long-lasting protection against repeated exposures to human immunodeficiency virus (HIV). Scientists at Emory University and GeoVax Labs, Inc. developed a vaccine that has protected nonhuman primates against multiple exposures to simian immunodeficiency virus (SIV) given in three clusters over more than three years. SIV is the nonhuman primate version of HIV.

Harriet L. Robinson, PhD, chief scientific officer at GeoVax Labs, Inc., and former director of the division of microbiology and immunology at Yerkes National Primate Research Center, has been leading the research team with Rama Rao Amara, PhD, associate professor of microbiology and immunology, Yerkes National Primate Research Center and the Emory Vaccine Center.

The research was presented Wednesday at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, Wash.

The vaccine regimen included a DNA prime vaccine that co-expressed HIV proteins and granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF is a normal protein that promotes the initiation of immune responses and thus enhances the ability of the vaccine to elicit blocking antibodies for the SIV virus before it enters cells.

Vaccination consisted of two DNA inoculations at months 0 and 2 to prime the vaccine response and then two booster inoculations at months 4 and 6. The booster vaccine was MVA, an attenuated poxvirus expressing HIV proteins. Six months after the last vaccination, both vaccinated and unvaccinated animals were exposed to SIV through 12 weekly exposures, resulting in an 87 percent per exposure efficacy and 70 percent overall protection. Over the next two years uninfected animals were exposed multiple times in two more series, resulting in an 82 percent per exposure efficacy during the second series and an 84 percent per exposure efficacy during the third series.

"Repeated challenges in animals are used to mimic sexual transmission," says Robinson. "The hope is that the results in the nonhuman primate models will translate into vaccine-induced prevention in humans."

"It is impressive to note that protection could be observed against both neutralization sensitive and neutralization resistant viruses," says Amara.

Neutralization is the process by which some antibodies can block virus infection.

A first generation GeoVax DNA/MVA vaccine that does not co-express GM-CSF has shown excellent safety and reproducible vaccine responses in Phase 1 and 2a clinical trials in more than 400 uninfected people. These trials, supported and conducted by the National Institutes of Health HIV Vaccine Trials Network, have set the stage for the second-generation GM-CSF co-expressing vaccine to move from its initial Phase 1 safety testing slated to start in March of this year to a Phase 2b efficacy trial in participants who are at high risk of exposure to HIV. The vaccine is designed for a version of the virus prevalent in the Americas.


'/>"/>

Contact: Holly Korschun
hkorsch@emory.edu
404-727-3990
Emory University
Source:Eurekalert

Related medicine news :

1. Headaches May Plague Many With HIV/AIDS
2. Children with HIV/AIDS falling through the cracks of treatment scale-up efforts
3. Despite Advances, HIV/AIDS Still Takes Heavy Emotional Toll
4. Advocates Push for Greater Awareness of HIV/AIDS
5. Preventing HIV/AIDS 1 SMS at a time
6. Einstein to utilize electronic medical records system to analyze HIV/AIDS in central Africa
7. Boston Medical Center awarded $1M to expand HIV/AIDS patient care services
8. DNDi launches new drug development program to address treatment needs of children with HIV/AIDS
9. International AIDS Society urges world leaders at UN General Assembly High-Level Meeting on HIV/AIDS to integrate a fourth pillar -- HIV cure research -- into the global response to the epidemic
10. Key goals for building on 30 years of HIV/AIDS research
11. Preventing the spread of HIV/AIDS with humanized BLT mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 22, 2017 , ... Children’s National ... Heart Association (AHA) to launch a Rheumatic Heart Disease Center, with the goal ... of rheumatic heart disease (RHD) in high-risk, financially disadvantaged countries and low-income communities ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... announced today that it has received certification for ANSI/ASIS PSC.1-2012. The company’s work ... in environments where the rule of law has been degraded. The PSC.1 standard ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health ... Capital, a Nashville-based private equity firm, has invested $3.35 million in the company. ... time, and Claritas Capital offers the smart money, speed to market and accountability ...
(Date:6/20/2017)... ... June 20, 2017 , ... After months of negotiations, FaceCradle USA is proud to announce the ... June 21. , “Introducing our product on QVC is something we all worked hard to ... pillow to more than 90 million homes in the United States,” said FaceCradle USA President ...
(Date:6/20/2017)... ... June 20, 2017 , ... Fresenius Vascular Care, a national ... techniques to treat and manage a wide range of vascular conditions, has today announced ... more than 65 centers represented by more than 40 local brands, a phased rollout ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... , June 8, 2017  Less than a month ... more than 200,000 companies, including hospital networks, in over ... as one of the largest online extortion attempts ever ... healthcare market, it is imperative that providers understand where ... data from this — and many other very real ...
(Date:6/7/2017)... Endo International plc (NASDAQ: ENDP ) today ... R. Goodwin , U.S. District Court Judge for the ... entered a case management order in MDL 2325, American ... (the "MDL") that includes a provision requiring plaintiffs in ... specific causation within one hundred twenty (120) days of ...
(Date:6/5/2017)... 2017 The Cincinnati location ... Inc. (NYSE: DPLO), has been awarded a Top Workplaces ... Results are based on an employee survey administered by ... workplace improvement. The survey measures several aspects of workplace culture, ... ...
Breaking Medicine Technology: